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Background 
Prostate cancer has the second highest incidence of any cancer in England, and the highest 
for males,i with around 40,000 new cases each year.1 Significantly more people are 
diagnosed with prostate cancer than die from it, but it nevertheless leads to around 10,000 
deaths per year.1 It is primarily a disease affecting older males, with over half of new 
diagnoses being in those aged 70 and over.1 
Risk factors for prostate cancer include race (higher risk amongst black males, lower risk 
amongst Asian males), genetic factors (including hereditary cancer syndromes, particularly 
with BRCA2, MLH1 or MSH2 pathogenic variants), weight and height. 
There is no screening programme for prostate cancer in the UK. Well conducted systematic 
reviews and randomised controlled trials (RCTs) have found no impact on long-term 
mortality.4, 5 The US Preventive Services Task Force has recommended against PSA-based 
screening for prostate cancer in males aged 70 years and over, and has said that for males 
aged 55–69 years the decision should be an individual one.6 
Symptoms of prostate cancer are non-specific and are more likely to be caused by other 
conditions, such as benign prostate hyperplasia; they include: more frequent and/or difficult 
urination, increased urgency and leaking. Less common symptoms are erection problems 
and blood in urine or semen. In England, around half of prostate cancers are diagnosed 
following a two-week wait (TWW) urgent referral from a general practitioner (GP) with 
suspicion of cancer, while around a third result from other GP referrals.2, 3 GPs may offer a 
prostate specific antigen (PSA) test or a digital rectal examination (DRE). In specialist clinics, 
diagnostic tests include transrectal ultrasound (TRUS) and biopsy. 
i Throughout this protocol, male/female refers to sex (biological) while man/woman applies to gender (social) 
                                               
Treatments for prostate cancer depend on a number of factors, including the position and 
stage of the cancer. In some cases treatment may not be initiated immediately, but the 
cancer monitored instead (termed active surveillance or watchful waiting). Early prostate 
cancer may be treated with surgery or radiotherapy, and potentially with hormone therapy. 
More advanced cancer may be less amenable to surgery, and may be treated with 
chemotherapy. 
Weight and diet may be modifiable risk factors for prostate cancer, but other interventions for 
risk reduction have not proved effective. Finasteride and dutasteride have been investigated 
as chemoprevention in two placebo-controlled randomised trials, which found that although 
the agents reduced the overall incidence of prostate cancer, they did not lower the risk of 
more aggressive cancers (and increased the risk in the case of finasteride), did not reduce 
mortality, and had notable side effects, including erectile dysfunction, loss of libido and 
gynecomastia.7, 8 
As prostate cancer is very common, and it leads to morbidity, mortality and costs to health 
and social care services, it is important that decisions around prostate cancer are evidence-
based and consider the resource impacts on health services. Additional money spent on 
identifying or managing prostate cancer is money which cannot be spent on other health 
care activities, which may produce better outcomes for patients. This is true in publicly 
funded and private insurance based health care systems. 
Cost-effectiveness analyses evaluate the additional costs associated with interventions as 
well as their health consequences. In many cases the health consequences are measured in 
quality-adjusted life years (QALYs) so that they can be compared across different disease 
areas and intervention types. If the incremental cost-effectiveness ratio (ICER, the ratio of 
additional costs to additional benefits) is less than a threshold, the intervention is considered 
to be cost-effective. 
Cost-effectiveness analyses can be based on trials, in which costs and health outcomes are 
measured for participants with a long duration of follow-up, however this is costly and time 
consuming, so in many cases mathematical models are used to extrapolate results into the 
future, as well as to incorporate evidence from multiple sources. 
Whole disease modelling is an approach which makes it possible to evaluate the cost-
effectiveness of different interventions affecting different aspects of the disease pathway. It 
achieves this by modelling the whole disease pathway for individuals.9 For example, it 
makes it possible to compare a screening programme to a treatment option. Whole disease 
models take into account the downstream effects of interventions, and can even be used to 
evaluate different portfolios of interventions, in order to identify the most cost-effective 
combination of interventions. 
Whole disease models are more challenging to conceptualise, build and parameterise than 
models of a single point of intervention, but these more focussed models can offer valuable 
insights for the development of a whole disease model. 
We do not believe that there is any comprehensive review of economic models in prostate 
cancer, although a review by Sanghera et al.10 has reviewed economic models of screening 
interventions for prostate cancer. 
Aims and objectives 
The aim of the project is to identify and bring together all health economic modelling studies 
in prostate cancer, to inform the development of a whole disease model for prostate cancer. 
Note: It is not the aim of the project to identify parameters for the development of the whole 
disease model or to estimate the cost-effectiveness of any interventions for prostate cancer 
in any setting from the literature. 
The objective of the project is to conduct a systematic review of model-based economic 
evaluations in prostate cancer, including a narrative synthesis. 
Methods 
This protocol will be deposited in the University of Exeter institutional repository (ORE) prior 
to the study selection component of the review. 
Study identification 
The strategy for identifying studies will include searches of electronic bibliographic 
databases (and backward citation tracking on included studies (i.e., searching the reference 
lists of included studies). The websites of the National Institute for Health and Care 
Excellence (NICE) and the UK National Screening Committee will also be searched for 
technical reports relating to prostate cancer. Any existing systematic reviews of economic 
evaluations in prostate cancer which include modelling studies will be noted and their 
reference lists also scrutinised. 
Study selection 
Two or more researchers will independently examine titles and abstracts for potential 
eligibility for inclusion. Disagreements will be resolved by discussion between the 
researchers. A random sample of 100 titles and abstracts will be used to pilot the inclusion 
criteria and to improve concurrence between reviewers. 
Full text articles will be retrieved where reviewers agree the article may be eligible for 
inclusion or when there is no consensus. Two or more researchers will independently 
examine the full text articles to determine eligibility for inclusion. Disagreements will be 
resolved by discussion between the researchers with the involvement of an additional 
reviewer if necessary. 
Table 1: Inclusion criteria for the systematic review 
Criteria Include Exclude 
Population Males with prostate cancer 
Males with symptoms that may indicate prostate cancer 
Males with risk factors for prostate cancer 
Males (generally) at risk of prostate cancer 
 
Interventions 
and 
comparators 
Interventions to manage prostate cancer 
Interventions to improve the diagnosis of prostate cancer 
Surveillance for prostate cancer 
Screening interventions for prostate cancer 
Interventions to reduce the risk of prostate cancer 
Studies with a single arm 
(i.e., no comparator) 
Forms of 
economic 
evaluation 
Cost-effectiveness analyses 
Cost-utility analyses 
Cost-consequences analyses 
Cost-benefit analyses (where health consequences are 
valued in monetary units) 
Cost studies 
Cost-minimisation 
analyses 
Preference-elicitation 
studies 
Economic burden studies 
Reviews of economic 
evaluations 
Study designs Model-based economic evaluations, including (but not limited 
to): decision trees, cohort models (Markov cohort simulation 
and partitioned survival analyses), simulation methods 
(Markov microsimulation, discrete event simulation, agent-
based modelling, system dynamics), and hybrid models 
Economic evaluations not 
using modelling, such as 
economic evaluations 
based solely on trial data 
Other  Studies only published in 
abstract form 
 
Data abstraction 
Two or more researchers will independently complete data abstraction of the included 
studies into pre-designed templates. The items for data abstraction will be focussed on 
methodology, and will not include the results of the included studies. A random sample of 
five studies will be used to pilot the data abstraction templates to improve concurrence 
between reviewers and to identify any need for modifications to the templates. 
Critical appraisal 
Critical appraisal is typically conducted in systematic reviews of economic evaluations so 
that the results from different studies can be weighed against their internal validity (risk of 
bias). This review is focussed on the methodology used in existing modelling studies, and 
will therefore include a selection of items from the Philips model checklist.11, 12 
Data synthesis 
Narrative synthesis will be conducted, supported by tables of study characteristics. Studies 
will be divided according to their part in the prostate cancer pathway (e.g., prevention, 
diagnosis, early stage treatment, late stage treatment). 
Analysis 
A health economist with experience of cost-effectiveness modelling and systematic review 
will analyse the results of the review to draw conclusions to support future development of a 
whole disease model and to identify any areas where further research is needed to support 
modelling. 
Reporting 
The systematic review will be reported in an article submitted to a suitable journal, and will 
follow the PRISMA guidelines for reporting systematic reviews. 
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Appendix 1. Sample search strategy (MEDLINE) 
1. exp Prostatic neoplasms/ 
2. (prostat$ adj3 (cancer$ or carcinoma$ or tumor$ or tumour$ or malignan$ or 
neoplas$)).tw. 
3. (gleason adj3 (grad$ or scor$)).tw. 
4. or/1-3 
5. exp "Costs and cost analysis"/ 
6. (model adj3 (economic or cost)).ti,ab,kw. 
7. (cost adj3 (effect$ or util$)).ti,ab,kw. 
8. (economic adj3 (anal$ or eval$)).ti,ab,kw. 
9. natural history model.ti,ab,kw. 
10. screen$ model$.ti,ab,kw. 
11. disease progression model$.ti,ab,kw. 
12. or/5-11 
13. 4 and 12 
